FTXH News and Press, First Trust Nasdaq Pharmaceuticals ETF From 07/23/19

By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...

By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA and Denny Fish Portfolio Managers Andy Acker and Denny Fish explore disruptive forces in healthcare and technology. Disruption is being felt across industries and geographies and proving to be a differentiator in the long-term performance of investors' portfolios. Su...

By Tony DeSpirito Markets tend to focus on one risk at a time, and it’s fragile U.S.-China relations that are front and center now. New blog contributor Tony DeSpirito offers up two potential takeaways for equity investors. Headlines over the U.S.-China trade dispute have been p...

First Trust Advisors L.P. ("FTA") announces the declaration of distributions for 115 exchange-traded funds (each a “Fund,” collectively, the “Funds”) advised by FTA. The following dates apply to today's distribution declarations: FTA is a federally registe...

With yet another US Senate hearing having been held in late February , prescription drug prices have been continuously receiving a lot of attention. While an eventual solution to brand name pricing may take a number of years, changes to the generic industry may be coming quicker. Over the pas...

By Ethan Lovell and Rich Carney, CFA The U.S. Department of Health and Human Services wants to eliminate drug manufacturer rebates in Medicare, a move that could improve affordability for consumers. Portfolio Manager Ethan Lovell and Research Analyst Rich Carney, of the Global Life Scienc...

For those of you investing in Big Pharma, you may want to keep a close eye on developments in Washington over the next two years. The cost of pharmaceuticals may very well be the number one issue leading up to the 2020 election, and this year it may very well be different. This year, the Dem...